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In light of the complex nature of multiple sclerosis (MS) and the recently estimated
contribution of low-frequency variants into disease, decoding its genetic risk
components requires novel variant prioritization strategies. We selected, by reviewing
MS Genome Wide Association Studies (GWAS), 107 candidate loci marked by
intragenic single nucleotide polymorphisms (SNPs) with a remarkable association
(p-value ≤ 5 × 10−6). A whole exome sequencing (WES)-based pilot study of SNPs
with minor allele frequency (MAF) ≤ 0.04, conducted in three Italian families, revealed
15 exonic low-frequency SNPs with affected parent-child transmission. These variants
were detected in 65/120 Italian unrelated MS patients, also in combination (22
patients). Compared with databases (controls gnomAD, dbSNP150, ExAC, Tuscany-
1000 Genome), the allelic frequencies of C6orf10 rs16870005 and IL2RA rs12722600
were significantly higher (i.e., controls gnomAD, p = 9.89 × 10−7 and p < 1 × 10−20).
TET2 rs61744960 and TRAF3 rs138943371 frequencies were also significantly higher,
except in Tuscany-1000 Genome. Interestingly, the association of C6orf10 rs16870005
(Ala431Thr) with MS did not depend on its linkage disequilibrium with the HLA-DRB1
locus. Sequencing in the MS cohort of the C6orf10 3′ region revealed 14 rare mutations
(10 not previously reported). Four variants were null, and significantly more frequent than
in the databases. Further, the C6orf10 rare variants were observed in combinations,
both intra-locus and with other low-frequency SNPs. The C6orf10 Ser389Xfr was found
homozygous in a patient with early onset of the MS. Taking into account the potentially
functional impact of the identified exonic variants, their expression in combination at
the protein level could provide functional insights in the heterogeneous pathogenetic
mechanisms contributing to MS.
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INTRODUCTION
Multiple Sclerosis (MS) is a chronic autoimmune disease of
the central nervous system (CNS), involving inflammatory-
based mechanisms and characterized by demyelination,
neurodegeneration and progressive accumulation of neurological
dysfunction (Ciccarelli et al., 2014). The heterogeneous
manifestation and clinical course of MS are explained by its
complex multi-factorial nature, where the interaction of genetic,
lifestyle, and environmental factors confer the susceptibility
(Morandi et al., 2015; Olsson et al., 2017). The heritable
contribution to MS risk is supported by investigations on
families (Patsopoulos, 2018).
To date, the majority of genetic studies on MS have been
focused on susceptibility variants. In particular, several genome-
wide association studies (GWAS), and subsequent replication
studies, have identified hundreds of variants within susceptibility
gene loci (Bashinskaya et al., 2015).
The single nucleotide polymorphisms (SNPs) identified
through GWAS are mainly located within non-coding regions
of the genome, which could pinpoint the presence of disease-
associated variants in linkage disequilibrium.
The very recent study, made by the International Multiple
Sclerosis Genetics Consortium, provides for the first time the
evidence that low-frequency variants (minor allele frequency,
MAF < 5%) explain 11.34% of the observed difference between
cases and controls (International Multiple Sclerosis Genetics
Consortium, 2018). The majority of low-frequency variants
which contributed to MS risk were not individually detectable
at genome-wide thresholds and among those associated with
MS, only 1/3 were in linkage disequilibrium with the common
variants from the GWAS (International Multiple Sclerosis
Genetics Consortium, 2018).
Genetic studies in MS have used whole exome sequencing
(WES) to investigate somatic mutations (Kemppinen et al., 2014),
to define the genetic contribution to MS clinical outcomes
(Sadovnick et al., 2017) and to suggest new potential causative
variants in families (Dyment et al., 2012; Garcia-Rosa et al.,
2017; Maver et al., 2017; Mescheriakova et al., 2018) or unrelated
patients (Bernales et al., 2018). WES data in families, suggesting
monogenic disease forms caused by rare variants with strong
functional impact (Ramagopalan et al., 2011; Wang et al.,
2016), were not confirmed in the subsequent replication studies
(Ban et al., 2013; International Multiple Sclerosis Genetics
Consortium, 2016; Minikel and MacArthur, 2016). Based on the
aforementioned findings, decoding the genetic risk components
of MS still represents a challenge, and novel strategies are
required to prioritize variants (Wang and Biernacka, 2015).
We set up a targeted WES-based pilot study in MS families,
followed by low-frequency variants investigation in a cohort
of unrelated patients in Italy, where a high prevalence and
incidence of MS have been reported (Battaglia and Bezzini, 2017;
Granieri et al., 2018).
The main aim of this study was to identify new exonic
and potentially functional low-frequency variants for MS
risk within genes marked by intragenic common variants
from the GWAS.
MATERIALS AND METHODS
Study Population
The study population included (i) three Italian families with MS-
affected members (clinical characteristics and pedigree shown
in Figure 1) and (ii) 120 Italian unrelated MS patients coming
from the mainland, selected from previous studies (Gemmati
et al., 2012; Marchetti et al., 2018; Ziliotto et al., 2018) for
having age of MS onset under 52 and mean age of MS onset
(34.5 ± 9.7) similar to that of the affected family members
(34.1 ± 8.2; Student’s t-test p-value = 0.371). MS diagnosis
was assessed according to the 2010 revised McDonald criteria
(Polman et al., 2011). All MS patients underwent neurological
visits, MRI examinations and assessment of the Expanded
Disability Status Scale (EDSS) (Kurtzke, 1983). All patients were
over 18 years of age and the patients’ medical records were
examined in order to ascertain age of diagnosis and type of
MS at the time of blood sample collection. Among the 120
unrelated MS patients, 44 patients were relapsing remitting
MS (RR-MS), 53 were secondary progressive MS (SP-MS) and
23 had primary progressive (PP-MS) course of the disease.
Written informed consent was obtained from all subjects, and
the study was approved by the Ethical Committee of the S. Anna
University-Hospital, Ferrara, Italy. Demographic and clinical
characteristics of the unrelated MS patients are summarized
in Table 1.
Search Strategy and Selection Criteria of
Candidate Genes
A systematic review of the literature was performed for all
years available through December 31, 2017. The primary source
was the PubMed database1, for which search terms “GWAS”
and “multiple sclerosis” were used. Further search included
NHGRI-EBI GWAS catalog2. Variants identified by GWAS in
MS were selected for being intragenic, non-HLA, and having
p-value ≤ 5 × 10−6. On the basis of these selected common
variants, we generated the final gene reference list for the
present study (Supplementary Table 1). The study design is
schematically described in Figure 2.
Whole-Exome Sequencing and Analysis
The genomic DNA (gDNA) was extracted from peripheral
blood using the Wizard R© Genomic DNA Purification Kit
(Promega, Madison, WI, United States). WES was performed
on eleven individuals, seven diagnosed with MS and four
unaffected, from three independent families (Figure 1).
Sequencing was performed by BGI (Shenzhen, China) using
nanoarray-based short-read sequencing-by-ligation technology
(cPALTM). Reads were mapped against the hg19 human reference
sequence3 using SOAPaligner4. Variants calling was performed
1http://www.ncbi.nlm.nih.gov/pubmed/
2http://www.ebi.ac.uk/gwas
3http://genome.ucsc.edu/
4http://omictools.com/soapaligner-tool
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FIGURE 1 | Pedigree of families (A–C) with multiple sclerosis and clinical characteristics of the affected family members, RR-MS, relapsing-remitting multiple
sclerosis; SP-MS, secondary-progressive multiple sclerosis; PP-MS, primary progressive multiple sclerosis; EDSS, expanded disability status scale. EDSS ranges
from 0 to 10 in 0.5-point increments; higher scores indicate more disability.
TABLE 1 | Demographic and clinical characteristics of the unrelated MS patients cohort.
Clinical phenotype
All MS RR-MS SP-MS PP-MS p-value
Sample size, n 120 44 53 23
Female, n (%) 74 (61.7) 27 (61.4) 31 (58.5) 16 (69.6)
Onset, mean y ± SD 34.5 ± 9.7 33.9 ± 9.3 32.9 ± 9.5 39.1 ± 9.8 0.032
EDSS at examination, median (IQR) 6 (2–6.5) 2 (1–2.5) 6.5 (6–6.5) 6 (6–6.5) <0.0001
RR-MS, relapsing-remitting multiple sclerosis; SP-MS, secondary-progressive multiple sclerosis; PP-MS, primary progressive multiple sclerosis; n, number; SD, standard
deviation; y, years; EDSS, expanded disability status scale; IQR, inter quartile range. Descriptive analysis between RR-MS, SP-MS, and PP-MS was performed using
ANOVA for age of onset, and Kruskal–Wallis test for EDSS at examination. Multiple comparison tests provided differences in age of onset between SP-MS and PP-MS
(p = 0.031, Bonferroni’s test), and in EDSS of RR-MS with SP-MS and with PP-MS (both p < 0.0001, Dunn’s test).
with the Complete Genomics Small Variant Caller5. Genetic
variations were verified in: (i) the database of Single-Nucleotide
Polymorphisms (dbSNP, Build 1506), (ii) the 1000 Genomes
Project databases7, (iii) the Exome Aggregation Consortium
(ExAC8), and (iv) controls of Genome Aggregation database
(gnomAD v2.1.1 controls9).
The coverage of the target region was 99.26%, the average
depth on target region was 129X and the target coverage with
at least 20× was 90.6%. The filtering performed on WES-data
is schematically described in Figure 2. In order to remove
systematic artifacts, we visually verified the filtered low-frequency
variants with IGV10. We considered a variant as true heterozygous
with a call of 40% of the total reads.
5http://www.completegenomics.com/documents/Small_Variant_Assembler_
Methods.pdf
6http://www.ncbi.nlm.nih.gov/projects/SNP/
7http://www.1000genomes.org/data
8http://exac.broadinstitute.org/
9https://gnomad.broadinstitute.org/
10http://software.broadinstitute.org/software/igv/
The effects of new coding variations on protein structure
and function were predicted using Provean/SIFT11, while the
effects of low-frequency coding variations, already reported on
databases as prediction by SIFT/PolyPhen, were extrapolated
from Ensembl12. The whole-exome sequencing dataset generated
during the current study is available in the https://www.ncbi.nlm.
nih.gov/sra (Accession Number: PRJNA544162).
Mutation Screening
Low-frequency variants, identified through the filtering in MS
families, were confirmed by Sanger sequencing (n = 13) or
restriction analysis (n = 2, ADAMTS3 and GC). Primers
to amplify the coding sequences containing the identified
low-frequency variants were designed with Primer3 software
v0.04.013. A total of 50 ng of gDNA was amplified by polymerase
chain reaction (PCR) using a standard protocol with AmpliTaq
Gold 360 DNA polymerase (Applied Biosystems, Foster City,
11http://sift.jcvi.org/www/SIFT_enst_submit.html
12http://www.ensembl.org/index.html
13http://bioinfo.ut.ee/primer3-0.4.0/
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FIGURE 2 | Study design. Multiple sclerosis (MS) GWAS and WES SNP
filtering is schematically described. In light blue, the search strategy and
selection criteria of candidate genes; in orange the Whole-exome sequencing
and the analysis on MS families; in green the screening strategy in the
unrelated MS patients.
CA, United States) (Balestra et al., 2016). PCR conditions were
set up as follows: an initial denaturation at 94◦C for 5 minutes
and then at 65◦C for 3 minutes, followed by 35 cycles at
94◦C for 30 seconds, specific temperatures for each couple
of primers for 30 seconds, 72◦C for 30 second or 1 minute,
and a final elongation at 72◦C for 7 minutes. Detailed primer
sequences and PCR conditions used for Sanger sequencing are
reported in Table 2. The PCR products were purified with
CleanSweepTM PCR Purification (Applied Biosystems) prior to
direct sequencing (Macrogen, Madrid, Spain). Sequences were
analyzed using the software NovoSNP (Weckx et al., 2005).
Size of PCR amplicons and restriction products were examined
through agarose gel electrophoresis.
The presence of the selected low-frequency variants was
investigated in a sample set of 120 Italian unrelated MS patients
through Sanger sequencing (Table 2) or restriction analysis
using the primer sequences and the restriction enzymes reported
in Table 3.
Bio-Informatics Analysis of Nucleotide
Changes
The prediction of mi-RNA targets was conducted by using the
tool at www.mirdb.org exploiting the support vector machines
(SVMs) procedures. The computational prediction of splice sites
and or splicing regulatory elements was conducted by using the
www.umd.be/HSF/ online software.
Statistical Analysis
For populations comparison, we used MAFs obtained from:
(i) the “dbSNP Build 150” (Homo sapiens Annotation
Release 108) which combines all available frequencies from
submitted SNPs clustered together into a reference SNP,
(ii) the ExAC, which includes exome sequencing data from
a wide variety of large-scale sequencing projects and in
particular of European (not-Finnish) individuals, (iii) controls
of gnomAD, which includes only samples from individuals
who were not selected as a case in a case/control study
of common disease, and (iv) 1000 Genome Project which
contains allelic frequencies for a sample of 107 subjects
from Tuscany, Italy, an optimal reference population for
our MS individuals. The low prevalence (188 per 100’000
individuals) of MS in Tuscany (Bezzini et al., 2016) makes
improbable the presence of individuals with MS in the
Tuscany control sample.
TABLE 2 | Primer sequences and PCR conditions used for Sanger sequencing.
Gene SNP position
GRCh37/hg19
SNP ID Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′) Tm (◦C) Length (bp)
ANKRD55 5:55407449 rs77017041 TTGTCACTCCAGTTCCTAGCTT CCTGATGAAGCATGTGGAAT 60 850
C6orf10 6:32261153 rs16870005 TTTAGGCAATGGCTGGGATA TGTGCCAAGAAGACAGGAATC 60 658
CD86 3:121774281 rs11575853 TCTTCCTCAAGTGTGGTCAAAA GCACCATCTTCAACCTCAGC 60 297
EVI5 1:92979432 rs41286809 TGGCAATGGTAAATCAGTGG CATGGAATGTTTGCTTTTTGG 60 595
IL2RA 10:6054765 rs12722600 ATAGAGACAAGGTTGCCACTGC CCACAGCTATTGTCTGCCATATAAA 66 468
MALT1 18:56367823 rs74847855 CACTTTCAAAGCTTCATACTGAAATC AAGACAAAACACATGGATCAAATCT 60 427
MMEL1 1:2530169 rs147248515 TAACCCCTCATGTCCCACAC GGGGCTGGGTTTCTTAGATT 63 353
STAT4 2:191899319 – GAAATTCTCAAAACCCCATGT AAATTGAGCACAAAATTGAAGC 60 209
TET2 4:106156163 rs61744960 TATTATCCAGATTGTGTTTCCATTG CTTAGTGAACACTGAGCTTTGCTT 63 471
TOP3A 17:18217958 rs2230153 TCGCCTTCATCTCGATTCTT TGAGCCTCATCTCTGGCTTC 55 342
TRAF3 14:103371923 rs138943371 ATGTGTGCCAGGGTCTACCT TCTTGAAGCTGCTGCTGTTG 63 220
WWOX 16:78458807 rs7201683 AAAGAATTTCTCATTCCCGAAG CACCCACATGTCTCAAGCAG 60 444
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To test the difference in MAFs between reference populations
and the allelic frequencies observed in the study population, a
two-proportion z-test, with a 0.05 two-sided significance level,
was applied. A threshold of p < 0.0042, assuming the Bonferroni
correction for multiple testing, was used for significance.
The potential enrichment of exonic low-frequency variants
in MS patients was evaluated using a permutation approach
based on the observed exonic polymorphisms. We first generated
the null distribution of the number of low-frequency variants
in a random sample of 107 genes, considering the exons
composing the longest isoform of each gene, as defined by
the human genome annotation (GRCh37/hg19). We took into
account both the number and the length of exons, dividing
the number of low-frequency variants by the total exon length,
for each gene set. Then, we repeated the permutation process
1,000 times and the empirical p-value was defined as the
proportion of replicates showing a number of variants higher
than the observed value.
RESULTS
Selection of Candidate Genes
Since GWAS and classical linkage studies have extensively
investigated the HLA locus, harboring the greatest genetic risk for
MS (reviewed in Hollenbach and Oksenberg, 2015), HLA genes
were not included in this study.
The review of GWAS in MS literature, reporting
polymorphisms associated with MS in case-control studies,
identified 141 variants which were selected for being intragenic
and for having a p-value ≤ 5 × 10−6, an arbitrary threshold
potentially highlighting genes with remarkable disease
association. These common variants established the list of
107 genes used for the purpose of this study. Variants and
corresponding genes are listed in the Supplementary Table 1.
Search for Low-Frequency Variants in
MS Families by WES
WES was performed in three independent Italian families with at
least two affected members in each pedigree (Figure 1).
A targeted analysis within the 107 MS susceptibility genes was
conducted in all pedigree members. SNPs with MAF≤ 0.04 were
taken into account when present in at least one affected family
member. The selection of SNPs with MAF ≤ 0.04 was aimed at
filtering low-frequency variants which did not emerge in GWAS.
These filtering criteria revealed 17 exonic mutations (ten
missense and seven synonymous) and three in the UnTranslated
Regions (UTRs), all in the heterozygous condition (Table 4).
Among the 20 exonic and UTRs variants, nine were present
only in the affected members of the families (rs77017041,
ANKRD55; rs16870005, C6orf10; rs41286809, EVI5; rs76781122,
GC; rs147248515, MMEL1; the new synonymous variant on
STAT4; rs61744960, TET2; rs138943371, TRAF3; rs12720355,
TYK2) and 14 variants were detected in at least two affected
family members with parent-child transmission.
The number of low-frequency exonic variants in these
families was investigated by a permutation test. No significant
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difference was observed between our result and that expected by
chance (p = 0.231).
Screening of WES-Selected Low
Frequency Variants in Unrelated Multiple
Sclerosis Patients
We focused our investigation on the 14 low-frequency variants
with parent-child transmission and on the new variant of
ADAMTS3 (Table 5). The 15 candidate SNPs were explored in
a sample set of 120 Italian unrelated MS patients (Table 1).
The predicted effects of the 15 analyzed low-frequency
variants, each on the main encoded transcript, are reported
in Table 5. In addition to the mutation of the start
codon (GC, Met1Ile), expected to reduce the amount of
the translated protein, missense variants were predicted
as damaging (ANKRD55 Ser376Pro; TET2 Gly355Asp)
or potentially damaging (MMEL1 Pro368Thr). For the
rs147248515 (MMEL1) the proline to threonine change
produced discrepant predictions. Among the four SNPs
predicted as benign, two cause noticeable changes in amino
acid polarity and size (Arg to Gly in MALT1; Ala to Thr
in C6orf10).
Aimed at prioritizing low-frequency variants that may
contribute to the disease-risk, we compared the MAFs observed
in the unrelated MS cohort with those reported in public
databases (Table 5). The new variants on STAT4 and ADAMTS3
genes were not found in the cohort of unrelated MS.
The allelic frequencies of C6orf10 rs16870005 and IL2RA
rs12722600 resulted significantly higher in MS patients compared
with all the databases (even after Bonferroni’s correction).
Based on frequencies in the Control gnomAD, the OR
for the rs1687005 risk T-allele was 4.57 (95% CI 2.33–
8.97) and the odds ratios for the rs12722600 risk T-allele
was 9.88 (95% CI 5.71–17.09), both highly significant (p-
value < 0.001).
The TET2 rs61744960 and TRAF3 rs76781122 showed
significant MAF differences between MS patients and public
databases with the exception of a nominal borderline p-values
with the Italian Tuscany population. On the other hand, TOP3A
rs2230153 showed significant MAF differences between MS
patients and public databases, with the exception of dbSNP150.
For two SNPs (CD86, rs11575853 and GC, rs76781122)
significant differences were observed only in the comparison
between MS patients and the dbSNP150 population. Of note,
for the MALT1 rs74847855, and WWOX rs7201683 highly
significant MAFs differences between MS and Tuscany subjects
were observed, that may reflect increased frequency of low-
frequency alleles in MS Italian patients.
Within the unrelated MS cohort, 17 patients were carriers of
two low-frequency variants and five patients were carrier of three
variants. The combinations repeatedly included the C6orf10,
TET2, and IL2RA variants (Table 6). The variants detected in
combination were always located on different chromosomes.
The IL2RA rs12722600 and the TRAF3 rs138943371 were
detected in the homozygous condition.
TABLE 4 | List of low-frequency variants identified in the MS families.
Gene SNP position
GRCh37/hg19
SNP ID MAF % dbSNP150 MAF %
ExAC
European
(not Finnish)
MAF %
controls
GnomAD
European
(not Finnish)
Mutation type SNPs carriers
ADAMTS3 4:73178175 rs150270324 0.926 1.34 1.12 Missense A-I-2+ A-II-3
ADAMTS3 4:73414590 – 0 0 Missense B-I-1+ B-II-3+ B-II-4
ANKRD55 5:55407449 rs77017041 0.427 0.63 0.71 Missense C-I-2+C-II-3
BTNL2 6:32363893 rs28362679 1.825 – 0 Missense B-I-1+ C-I-1+ C-I-2
C6orf10 6:32261153 rs16870005 1.250 1.43 0.85 Missense B-I-2+ B-II-3
GC 4:72669661 rs76781122 1.611 3.35 2.77 Missense B-I-2+ B-II-3
MALT1 18:56367823 rs74847855 3.734 4.28 4.20 Missense B-I-2+ B-II-3+ B-II-4
MMEL1 1:2530169 rs147248515 0.022 0.028 0.037 Missense B-I-2+ B-II-3
TET2 4:106156163 rs61744960 2.641 3.77 3.69 Missense B-I-2+ B-II-3+ C-I-2+C-II-3+ A-I-1+A-II-4
WWOX 16:78458807 rs7201683 1.989 1.23 1.11 Missense B-I-2+ B-II-3+ B-II-4+ C-I-2
EVI5 1:92979432 rs41286809 1.116 1.55 1.61 Synonymous C-I-2+C-II-3+ A-I-1+ A-II-3+ A-II-4
GC 4:72620788 rs76803094 1.799 2.56 2.14 Synonymous B-I-1+ B-II-3+ B-II-4
GEMIN2 14:39587220 rs150986614 0.251 0.37 0.37 Synonymous A-I-2+ A-II-3+ A-II-4
STAT4 2:191899319 – – – Synonymous C-I-2+C-II-3
TRAF3 14:103371923 rs138943371 0.245 0.30 0.36 Synonymous C-I-2+C-II-3
TOP3A 17:18217958 rs2230153 1.692 0.46 0.36 Synonymous C-I-2+C-II-3+ A-I-2
TYK2 19:10472452 rs12720355 0.962 1.38 1.45 Synonymous C-I-2+C-II-3
CD86 3:121774281 rs11575853 1.078 – 3.1 UTR 5′ B-I-2+ B-II-3+ C-I-1
IL2RA 10:6054765 rs12722600 1.777 – 0.87 UTR 3′ B-I-2+ B-II-3+ C-I-1+ C-II-3
RRAS2 11:14300827 – – – UTR 3′ B-I-2+ B-II-4
In bold the genes including the exonic variants present only in affected family members defined as in Figure 1.
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TABLE 5 | Selected rare variants in the cohort of 120 unrelated multiple sclerosis patients.
Gene SNP
position
GRCh37/
hg19
SNP ID Transcript
(exon)
Amino acid
change
SIFT/
PolyPhen
prediction
Nucleotide
change
MAF %
in MS
patients
alleles
n = 240
(n alleles)
MAF %
1000 GP
(Tuscany)
alleles
n = 214
MAF %
dbSNP150
MAF %
ExAC
European
(not
Finnish)
MAF %
controls
GnomAD
European
(not Finnish)
P-value◦
(Tuscany)
P-value◦
(dbSNP150)
P-
value◦(ExAC)
P-value◦
(controls
GnomAD)
ADAMTS3 4:73414590 – ENST0000
0286657
(3/22)
Lys37Glu 0.17/−0.01$ T > C 0 (0) – – – – – – – –
ANKRD55 5:55407449 rs77017041 ENST0000
0341048
(10/12)
Ser376Pro 0.01/0.767 A > G 0 (0) 0.47 0.427 0.63 0.71 0.2871 0.3103 0.2174 0.1902
C6orf10 6:32261153 rs16870005 ENST000
00533191
(26/26)
Ala431Thr 0.46/0.028 C > T 3.75 (9) 1.4 1.250 1.43 0.85 0.0019 0.00049 0.0025 9.89 × 10−07
CD86 3:121774281 rs11575853 ENST000
00330540
(5′UTR)
−56bp from
+1 Met
n.a. A > G 3.75 (9) 2.8 1.078 – 3.1 0.3723 6.1 × 10−5 – 0.5612
EVI5 1:92979432 rs41286809 ENST000
00540033
(18/18)
Phe749Phe - G > A 0.83 (2) 0.47 1.116 1.55 1.61 0.4105 0.6768 0.3688 0.3391
GC 4:72669661 rs76781122 ENST0000
0504199
(1/14)
Met1Ile 0.2/0
Start codon
G > T 4.58 (11) 5.61 1.611 3.35 2.77 0.4895 0.00025 0.2883 0.0869
IL2RA 10:6054765 rs12722600 ENST000
00379959
(3′UTR)
+70 from
273 stop
n.a. G > A 7.92 (19) 4.21 1.777 – 0.87 0.0042 6.0 × 10−13 – <1.0× 10−20
MALT1 18:56367823 rs74847855 ENST000
00348428
(4/17)
Arg217Gly 0.69/0 A > G 4.58 (11) 1.9 3.734 4.28 4.20 0.0019 0.4877 0.8164 0.7672
MMEL1 1:2530169 rs147248515 ENST000
00378412
(12/24)
Pro368Thr 0.14/0.326 G > T 0 (0) 0 0.022 0.028 0.037 – – – –
STAT4 2:191899319 – ENST000
00392320
(18/24)
Gln525Gln - A > G 0∗ (0) – – – – – – – –
TET2 4:106156163 rs61744960 ENST000
00540549
(3/11)
Gly355Asp 0.01/0.282 G > A 8.33 (20) 5.6 2.614 3.77 3.69 0.0667 2.8 × 10−08 0.00021 0.00014
TOP3A 17:18217958 rs2230153 ENST000
00542570
(1/19)
Ala45Ala - G > A 1.66 (4) 0.47 1.692 0.46 0.36 0.0067 0.9757 0.0057 0.00073
TRAF3 14:103371923 rs138943371 ENST000
00347662
(11/11)
Ser478Ser - C > T 1.25 (3) 0.47 0.245 0.30 0.36 0.0773 0.00164 0.0071 0.02133
TYK2 19:10472452 rs12720355 ENST00
000525621
(13/25)
Ile651Ile - C > T 1.66 (4) 1.4 0.962 1.38 1.45 0.7251 0.2634 0.7034 0.77887
WWOX 16:78458807 rs7201683 ENST000
00566780
(7/9)
Leu216Val 0.19/0.04 C > G 2.08 (5) 0.47 1.989 1.23 1.11 0.00026 0.9166 0.2304 0.150086
The SIFT and PolyPhen scores (0.0 to 1.0) have opposite meanings. Prediction of the SIFT score ranges 0.0 to 0.05 deleterious; 0.05 to 1.0 tolerated. Prediction of the PolyPhen score ranges: 0.0 to 0.15, benign; 0.15 to 1.0 possibly damaging; 0.85 to
1.0 damaging. n.a., not applicable. $SIFT/Provean prediction for ADAMTS3 = (0.17) tolerated/(−0.01) neutral. ∗ Investigated in 218 alleles. ◦Bonferroni’s correction p-value set to 0.0042. Significant p-values are in bold.
Frontiers
in
G
enetics
|w
w
w
.frontiersin.org
7
June
2019
|Volum
e
10
|A
rticle
573
fgene-10-00573
June
26,2019
Tim
e:8:29
#
8
Ziliotto
etal.
C
6orf10
Variants
in
M
ultiple
S
clerosis
TABLE 6 | Unrelated multiple sclerosis patients carriers of at least 2 low-frequency variants.
ID Gender Age of MS
onset
Phenotype at
examination
C6orf10
rs16870005
CD86
rs11575853
EVI5
rs41286809
GC
rs76781122
IL2RA
rs12722600
MALT1
rs74847855
TET2
rs61744960
TOP3A
rs2230153
TRAF3
rs138943371
TYK2
rs12720355
WWOX
rs7201683
132 ZM F 20 RR Het Het
159 ZM M 26 RR Het Het
173 ZM F 31 RR Het Het
194 ZM F 31 RR Het Hom∗ Het
27-WP3 M 31 SP Het Het
43-WP3 F 31 PP Het Het
155 ZM F 33 SP Het Het
51-WP3 M 33 SP Het Het
109 ZM F 37 SP Het Het
63-WP3 F 37 SP Het Het Het
115 ZM F 38 SP Het Het Het
69-WP3 M 40 SP Het Het
111 ZM F 41 RR Het Het Het
49-WP3 F 42 PP Het Het
57-WP3 M 42 SP Het Het Het
208 ZM F 44 RR Het Het
MS18 F 45 SP Het Hom∗
184 ZM M 47 SP Het Het
192 ZM F 48 RR Het Het
72-WP3 F 48 PP Het Het
204 ZM M 50 RR Het Het
MS07 M n.d.§ SP Het Het
The heterozygous (Het) or homozygous (Hom∗) condition of the variants is specified. In bold, patients with combination of 3 low-frequency variants. §Age of onset below 50 years old.
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The comparison of age of MS onset between patients with
or without the 15 investigated low-frequency variants did not
provide significant differences.
Detection of Null Mutations in the 3′
Exon of C6orf10
The rs16870005 within C6orf10, a scarcely investigated locus,
resulted the only missense variant with a significantly increased
frequency in our cohort compared to dbSNP-Build150, Tuscany
of 1000 Genome Project, ExAC -European (not Finnish)- and
Control gnomAD -European (not Finnish)- (Table 5) and, in
addition, it was frequently present in combination with other
low-frequency variants (Table 6). Further, the nucleotide change
C > T (rs16870005) in the 3′ region of the C6orf10 transcripts
would substitute threonine for alanine in the carboxyl-terminal
region of all the predicted proteins (reference transcript used for
the study shown in Figure 3).
Based on these observations we sequenced the region
chr6:32261295-32260757 in the 120 MS patients, which revealed
the presence of 14 low-frequency mutations (MAF ≤ 0.04), 10
not previously reported (Table 7).
Of note, two mutations predicted premature termination
of translation and two translational frameshift. Inspection
of C6orf10 variants (Figure 3) pointed out that the four
null mutations affected all C6orf10 transcripts. Among
these, the ENST0000442822.6, after splicing, is shorter and
encodes a different 3′ sequence. In the transcripts other
than ENST0000442822.6, null mutations would remove a
larger C-terminus portion (Figure 3) in which we detected
several missense SNPs.
For missense changes the algorithms predicted discordant
effects (Table 7), with the exception of the damaging
Gly477Val (rs7751028).
Several databases were inspected for low-frequency
(MAF ≤ 0.04) exonic variants within the full C6orf10 transcript
ENST00000533191.5 (total length 80 Kb), and for the presence
of null variants. In particular, (i) in the Control gnomAD
database 301 variants were found, of which 24 were nonsense
or frameshift, and (ii) in the ExAC database 271 variants were
found, of which 20 were nonsense or frameshift. The proportion
of null variants in the MS patients (4/14 within 538 bp) was
higher than that in the Control gnomAD (p = 0.0254, Maximum
Likelihood chi-square) and in the ExAC (p-value = 0.0184,
Maximum Likelihood chi-square).
The distribution of the 14 low-frequency C6orf10 variants
detected by Sanger sequencing in the unrelated MS patients
is shown in Table 8. The frameshift mutations, of which the
Ser389Xfr in the homozygous condition, were detected in two
patients with young age of disease onset (21 and 25 years). Three
patients were carriers of two/three missense C6orf10 mutations
(Table 8). None of the 14 low-frequency variants was associated
with the presence of the C6orf10 rs16870005.
Seven patients over the 11 carriers of the C6orf10 variants
were also carriers of SNPs detected in the family WES study
(Supplementary Table 2).
DISCUSSION
Taking into account the complex multi-factorial nature of
MS, and the recently estimated contribution of low-frequency
variants into disease risk, we aimed at investigating genetic
risk components through combination of variant prioritization
strategies. We explored by WES 107 candidate loci for exonic
low-frequency variants in three Italian MS families with two or
three affected members and validated the results in 120 unrelated
FIGURE 3 | Schematic representation of the sequenced region and mutations in the 3′ exon of C6orf10. The low-frequency variants discovered by 3′ exon
sequencing in the unrelated MS are reported upper the bar (light blue/gray) of the ENST00000533191.5 transcript, used as reference. The gray bar indicates the
repetitive regions, and the red bars the translational stop codons of transcripts. The reference nucleotide position in GRCh37/hg19 is also shown below the
transcript bars. The first variant identified by our WES is reported bold and red. The stop and frame shift variants are highlighted in bold and black. The transcript
ENST0000442822.6, the only one undergoing splicing and ending at position 32256398 of Chr 6, is represented as a green bar. A blue horizontal line highlights the
3′ region with the different reference nucleotide position for each transcript. The out of scale intron is indicated with an interruption symbol. The different numbering
of this transcript in the 3′ region is reported. The change in the reference nucleotide position in the ENST0000442822.6 starts after the aminoacid (aa) 453 at
position 32261063.
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TABLE 7 | Low-frequency variants in 3′ exon of C6orf10 detected by Sanger sequencing within the cohort of 120 unrelated MS patients.
SNP position
GRCh37/hg19
SNP ID Amino acid
change
Provean/SIFT
prediction
Nucleotide
change
MAF %
dbSNP150
MAF %
ExAC
European
(not
Finnish)
MAF %
Controls
GnomAD
European
(not
Finnish)
MAF % in
120 MS
patients (n
alleles)
6:32260761 – Glu561Asp (−1.16) neutral/
(0) damaging
C > G – – – 0.42 (1)
6:32260769 – Val559Leu (−0.86) neutral/
(0.31) damaging
C > G – – – 0.42 (1)
6:32260774 – Lys557Ile (−1.6) neutral/
(0.004) damaging
T > A – – – 0.42 (1)
6:32260878∗ – Asp522Asp neutral/tolerated G > A – – – 1.25 (3)
6:32260898∗ – Asp516Tyr (−2.38) neutral/
(0.011) damaging
C > A – – – 0.42 (1)
6:32260927∗ – Glu506Val (−1.42) neutral/
(0.028) damaging
T > A – – – 0.42 (1)
6:32260933∗ rs766126891 Asp504Val (−2.42) neutral/
(0) damaging
T > A 0.001 – – 0.42 (1)
6:32261014 rs7751028 Gly477Val (−3.43) deleterious/
(0.008) damaging
C > A 2.480 0.98 0.99 0.42 (1)
6:32261075 – Lys457stop Damaging T > A – – – 0.42 (1)
6:32261084 – Ser454Xfr Damaging A > insG – – – 0.42 (1)
6:32261093 – Gly451stop Damaging C > A – – – 0.42 (1)
6:32261158 rs114543649 Thr429Ser (1.30) neutral/
(1) tolerated
G > C 2.479 0.98 0.99 0.42 (1)
6:32261277 – Ser389Xfr Damaging T > delT – – – 0.83 (2)
6:32261291 – Gln385Glu (1.38) neutral/
(1) tolerated
G > C 2.482 0.98 0.99 0.42 (1)
The sequenced 3′ exonic region spans chr6:32261295-32260757 (GRCh37/hg19). The reference transcript is ENST00000533191.5, and the reference protein is
ENSP00000431199 (exon position 26/26). The Provean cut off: equal or below −2.5, deleterious; above −2.5, neutral. The SIFT score range prediction: 0.0 to 0.05
deleterious; 0.05 to 1.0 tolerated. All variants were detected in heterozygous condition with the exception of Ser389Xfr (homozygous condition, bold and black). ∗Position
in repetitive regions.
Italian patients. This experimental approach brought to attention
15 exonic variants, firstly selected for parent-child transmission
and further investigated for increased frequency as compared to
public databases. Among these, STAT4 and ADAMTS3 variants
were found to be private of the families under study, which might
support the notion that a proportion of the unexplained MS
heritability is accounted by additive effects of individual variants
(International Multiple Sclerosis Genetics Consortium, 2018).
Noticeably, our screening identified a number of significant
differences in the observed allelic frequencies as compared with
public databases. The observed MAFs, higher in the Italian MS
patients under study, point toward an increase in frequency of the
detected variants in patients as compared to healthy population.
The C6orf10 rs16870005 and IL2RA rs12722600 are the main
signals identified in our study, as confirmed by comparison
with all databases.
Through different experimental approaches, focused on low-
frequency variants, we report several and novel findings in the
C6orf10 locus. The 3′ region, including the potentially damaging
variant rs16870005 which resulted associated with MS in our
cohort, was found to contain 14 low-frequency mutations,
among which 10 not previously reported and four potentially
null variants. Furthermore, three patients showed combination
of the C6orf10 heterozygous low-frequency variants, one was
found to be homozygous for the Ser389Xfr, and seven displayed
combinations of C6orf10 with low-frequency variants in other
candidate genes. Although anecdotal, finding the homozygous
Ser389Xfr in a patient with early onset of the MS disease fosters
further investigation in relation to the recent study suggesting
that C6orf10 could be implicated in the age of onset of other
neurodegenerative disease (Zhang et al., 2018).
The interpretation of potential functional consequences
was hampered by the C6orf10 chromosomal location and
structure. As a matter of fact, this ORF is located on
chromosome 6p21.32, in the major histocompatibility complex
region which contains the major MS-associated risk gene HLA-
DRB1 (Bashinskaya et al., 2015). To evaluate if the signals
of associations between the C6orf10 variants could reflect
linkage disequilibrium (LD) with DRB1 SNPs reported in the
literature (reviewed in Bashinskaya et al., 2015), the data
from the 1000 Genome project were explored (Supplementary
Table 3). The low LD of C6orf10 rs16870005 with C6orf10
rs3129934 (r2 0.113), and with the HLA rs9271366 (r2 0.055),
suggests that the association between C6orf10 rs16870005
and MS does not simply reflect the LD with the HLA-
DRB1 locus.
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TABLE 8 | Low-frequency variant genotypes in 3′ exon of C6orf10 within the
unrelated MS patients.
ID Gender Age of MS
onset
Phenotype at
examination
C6orf10
138 ZM F 21 RR Ser454Xfr (Het)
221 ZM M 22 RR Val559Leu (Het)
Glu561Asp (Het)
150 ZM F 25 RR Ser389Xfr (Hom)
194 ZM F 31 RR Gln385Glu (Het)
Thr429Ser (Het)
Gly477Val (Het)
106 ZM M 32 SP Asp504Val (Het)∗
Asp522Asp (Het)∗
128 ZM F 32 RR Glu506Val (Het)∗
109 ZM F 37 SP Asp522Asp (Het)∗
115 ZM F 38 SP Lys457stop (Het)
MS23 F 38 RR Gly451stop (Het)
112 ZM F 41 RR Lys557Ile (Het)
25-WP3 F 51 PP Asp516Tyr (Het)∗
65-WP3 F 51 SP Asp522Asp (Het)∗
MS patients carrying low-frequency C6orf10 variants (within the region
chr6:32261295-32260757) are reported. The heterozygous (Het) or homozygous
(Hom) condition of the variants is specified. In bold and black, the C6orf10 stop
and frame shift variants. ∗C6orf10 variants in repetitive regions.
The C6orf10 structure comprises several transcripts, including
three isoforms of a validated, but not characterized, long non-
coding RNA (NR_136244.1, NR_136245.1, and NR_136246.1)
and a pseudogene hnRNP (HNRNPA1P2). Thus, the null
mutations that we have found in the MS cohort would affect the
C-terminal portion of several uncharacterized proteins expressed
in brain and B cells 14both tissues of interest for MS.
The small sample size and the statistical power derived from
our population do not permit an informative evaluation of the
possible impact of the numerous newly detected C6orf10 variants
on the disease onset or clinical course within an integrated
multiple variants model.
Finding of the IL2RA 3′UTR low-frequency variant
(rs12722600) (i) in two MS families, (ii) with a significantly
higher frequency in the unrelated MS cohort than in the
public databases, and (iii) in several combinations with the
other low-frequency SNPs, is particularly intriguing. As for the
other IL2RA polymorphisms previously associated with the
risk of developing the disease (Matiello et al., 2011; Wang and
Chen, 2018), the functional consequence of the rs12722600
can be only proposed (Maier et al., 2009) as affecting the
post-transcriptional regulation of the IL2RA mRNA, of which
little is known (Techasintana et al., 2017). Bio-informatics
prediction of miRNA binding sites in the IL2RA 3′UTR did
not reveal creation or disruption of regulatory sites produced
by the rs12722600 nucleotide change. Interestingly, therapies
for MS have been already developed to avoid the formation
of the interleukin-2 receptor complex, and particularly
targeting CD25 (Bielekova, 2018), the α-subunit encoded
14http://www.genenetwork.org/webqtl/WebQTL.py?cmd=sch&refseq=NM_
006781&species=human
by the IL2RA. Our findings support further studies aimed at
characterizing the IL2RA 3′UTR in patients undergoing this
therapeutic approach.
The TET2 gene codifies for an enzyme that catalyzes the
conversion of 5-methylcytosine to 5-hydroxymethylcytosine,
thus modifying the DNA methylation pattern. As functional
partner, TET2 may participate in histone modification (O-
GlcNAcylation, Chen et al., 2013). Noteworthy, demethylation
by TET2 is also actively involved in T cells differentiation
and their cytokines production (Ichiyama et al., 2015; Wang
et al., 2017). The presence of the low-frequency TET2
rs61744960 variant in MS patients of all the three families,
and its frequency in unrelated MS patients cohort higher
than in three databases support further investigation of
this finding in relation to MS. It is of note that the
SNP rs61744960 has been previously reported in an Italian
study focused on leukemia, and two of the six patients,
who carried this variant, had MS as a primary disease
(Ottone et al., 2012).
For the TRAF3 rs138943371 we observed in the four databases
a frequency pattern similar to that of TET2 rs61744960. TRAF3
gene codifies for tumor necrosis factor receptor-associated factor
3, a major regulator of innate immune response through
different transduction signal pathways (Cullell et al., 2017).
By “Human Splicing Finder” analysis, the rs138943371 C
to T change, disrupting an exonic splicing enhancer, might
create in the TRAF3 transcript a new exonic splicing silencer.
Further investigation is needed to evaluate potential effects on
transcription and splicing processes, that are strictly related and
rely on regulatory elements in the 3′ gene region.
Although in the GWAS MS candidate genes we did not
detect an increased number of low frequency variants in our
MS families, those variants firstly found with parent-child
transmission in MS families were detected in several
combinations in unrelated patients, particularly in C6orf10,
IL2RA and TET2. These observations further highlight the
complexity of the MS genetic risk components.
Our study supports further investigation within genetics
consortiums of multiple low-frequency risk variants in coding
regions of MS candidate genes. Expression of specific protein
variants, and their combinations, could provide functional
insights in the heterogeneous pathogenetic mechanisms
contributing to MS.
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